VolitionRx Limited (NYSEAMERICAN:VNRX) Sees Significant Decline in Short Interest

VolitionRx Limited (NYSEAMERICAN:VNRX) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 570,500 shares, a decrease of 20.3% from the December 15th total of 715,700 shares. Based on an average trading volume of 262,100 shares, the days-to-cover ratio is currently 2.2 days.

VolitionRx Stock Performance

Shares of VNRX stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.64. 8,887 shares of the stock traded hands, compared to its average volume of 96,740. The firm has a market cap of $40.44 million, a price-to-earnings ratio of -1.14 and a beta of 1.59. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.